Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
Cenexi reports an EBITDA breakeven for the quarter
Cenexi reports an EBITDA breakeven for the quarter
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated